Outlook Therapeutics Inc (OTLK)

[pfelgueiras]

Outlook Therapeutics is hoping to become the first and only company to commercialize an FDA-approved ophthalmic formulation of bevacizumab for use in wet AMD

https://www.proactiveinvestors.com/companies/news/947974/outlook-therapeutics-is-bringing-a-treatment-for-retinal-disease-to-the-market-at-the-right-time-947974.html

$OTLK Keep Buying and Holding for BIG PROFITS with the next 3 catalyst events:
1) Ongoing Phase 3 pivotal trial with topline data expected Q3 2021
2) Biologics License Application (BLA) submission on Q4 2021.
3) BLA FDA Approval in 1Q 2022.
After "Phase 3" topline data, OTLK "can have" a Buyout, I estimate it will be above $50,00 (see My View of Profits)